Avalo Therapeutics
AVTX • NASDAQ
Avalo Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Garry A. Neil, with a market cap of $316.5M.
CEOGarry A. Neil
Next Earnings
Upcoming earnings announcement for Avalo Therapeutics
Date
Monday, May 11, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$1.01
Earnings History
Past 12 earnings reports for Avalo Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 23, 2026 | Q4 2025 | -$0.48Est: -$1.51 | +68.2% | $59.0K | — |  10-K |
| Nov 6, 2025 | Q3 2025 | -$2.19Est: -$1.65 | -32.7% | - | — | 10-Q |
| Aug 7, 2025 | Q2 2025 | -$1.92Est: -$1.46 | -31.5% | - | — | 10-Q |
| May 12, 2025 | Q1 2025 | -$1.25Est: -$1.61 | +22.4% | - | — | 10-Q |
| Mar 20, 2025 | Q4 2024 | $1.72Est: -$1.39 | +223.7% | $192.0K | — | 10-K |
| Nov 7, 2024 | Q3 2024 | -$2.83Est: -$1.45 | -95.2% | $249.0K | — | 10-Q |
| Aug 12, 2024 | Q2 2024 | -$14.07Est: -$6.70 | -110.0% | - | — | 10-Q |
| May 13, 2024 | Q1 2024 | -$6.11Est: -$1.18 | -417.8% | - | — | 10-Q/A |
| Mar 29, 2024 | Q4 2023 | -$10.12Est: -$4.80 | -110.8% | $571.0KEst: $300.0K | +90.3% | 10-K |
| Nov 9, 2023 | Q3 2023 | -$26.40Est: -$264.00 | +90.0% | $236.0KEst: $1.0M | -76.4% | — |
| Aug 3, 2023 | Q2 2023 | -$141.60Est: -$192.00 | +26.3% | $643.0KEst: $500.0K | +28.6% | — |
| May 4, 2023 | Q1 2023 | -$204.00Est: -$232.80 | +12.4% | $475.0KEst: $1.0M | -52.5% | — |